Independent UK medicine guidance • Nutrition series
Calorie counting on Mounjaro: doing deficits safely
Tracking calories with an app suits people who like data and flexibility: nothing is banned, everything is measured. On Mounjaro, though, the job changes. Before treatment, tracking usually polices eating too much. On treatment, its most valuable role flips to making sure you are eating enough of the right things.
The mindset shift
Before treatment
The deficit is the hard part. Tracking exists to keep intake below expenditure against a strong appetite.
On treatment
The medicine creates the deficit. Tracking is now most useful as a floor, catching the days protein or total intake quietly collapses, and as a data trail for your prescriber.
Doing it well
- Get a personal range, not an internet number: needs vary with size, age, activity and health; your prescriber or a dietitian can set a sensible floor and ceiling
- Track protein as seriously as calories: it is the number most likely to fall short on treatment
- Watch the warning pattern: repeated days far below your range are a prescriber conversation, not an achievement
- Weigh trends, not days: daily fluctuations are noise; the weekly average is the signal
- Use the data at reviews: a simple intake and symptom log helps dose decisions enormously
When tracking stops helping
For some people, counting slides from useful into compulsive: anxiety when unable to log, shrinking safe-food lists, targets ratcheting ever lower, guilt over normal meals. On a medicine that already suppresses appetite, that combination can become genuinely harmful.
If tracking is driving restriction rather than nutrition, or if you have any history of an eating disorder, step away from the app and speak to your GP. Support is available through NHS talking therapies and eating disorder services, and treatment plans can be adjusted. This matters more than any weight goal.
Who should get advice first?
Seek advice first with diabetes on insulin or a sulphonylurea (planned intake changes affect hypo risk), kidney disease, pregnancy or breastfeeding (Mounjaro should not be used in pregnancy), under 18s, and anyone with a history of disordered eating.
Common questions
How many calories should I eat on Mounjaro?
There is no universal number. Needs depend on your size, age, activity and health, so ask your prescriber or a dietitian for a personal range with both a floor and a ceiling. What matters is a moderate, sustainable deficit with protein protected, not the lowest number you can reach.
Is eating very little a sign Mounjaro is working well?
No. Persistently very low intake drives muscle loss, fatigue, hair shedding and constipation, and makes regain more likely. If your logged intake keeps landing far below your range, that is a prescriber conversation rather than a success.
Do I have to count calories on Mounjaro?
No. No tracking method is required with treatment. Counting suits people who like data; others do better with simple structures like the Mediterranean pattern or protein-first plates. The best method is whichever keeps your nutrition adequate and your relationship with food healthy.
Primary sources: NHS Better Health weight loss plan • British Dietetic Association food facts • Mounjaro Patient Information Leaflet (eMC)
Explore the nutrition series
Every guide in the Monj nutrition series. The pink marker shows where you are now.
© 2026 Medstack Ltd. Written and published by Monj (monj.co.uk). You are welcome to link to this page or quote a short extract with a credit and a link. Republishing the text, page structure, safety-routing design or price data, in whole or in part, including to train or ground an automated system, is not permitted without written permission. See our independence statement and editorial and review policy.
Sources referenced on this page
Linked from the text above:
- NHS Better Health weight loss plan www.nhs.uk
- Mounjaro Patient Information Leaflet (eMC) www.medicines.org.uk
Standing primary references for every Monj page:
- Mounjaro (tirzepatide) Summary of Product Characteristics and Patient Information Leaflet, electronic medicines compendium
- MHRA Drug Safety Update: GLP-1 receptor agonists
- NICE TA1026: tirzepatide for managing overweight and obesity
- General Pharmaceutical Council register of pharmacies
- MHRA Yellow Card scheme
